Week of May 4 · Q2 2026

Good morning, Bilal.

4 active pursuits ·BX-3142 due in 7 days ·BX-3142 draft is 86% grounded
Senior time per RFP
25h → 2h
before Krux → with Krux
412 hours saved this quarter
Win rate (12mo)
50%
1W · 1L
+8% vs Q1
Flagged claims caught
38
overcommits caught pre-submission
this quarter
Cost-prediction accuracy
91%
vs. actuals on closed bids
↑ from 73% in month 1

Pipeline

4 active · 1 awaiting scoring
Sponsor / ProgramStageValueGroundingDueOwner
Northpath Bio
BX-3142, peptide GLP-1 analog (31-mer), 50 kg cGMP API
In Review$2.40M
86%
7d
BS
Boston Biotherapeutics
ADC small-molecule payload, cGMP
Proposal Sent$3.20M
92%
overdue
BS
Stellar Pharma
Solid oral formulation dev + Phase 1 supply
Negotiating$1.40M
78%
overdue
SN
MedVault Inc.
cGMP API, 25 kg, 6-step route
Qualifying$2.80M
--
15d
BS

Knowledge layers

every answer grounded
Customer data
8
TCG batch records, plant validation, sponsor history
Expert Knowledge
5
70+ yrs · J. Adams (BI) + C. Reyes (Merck)

Signal from closed deals

every outcome trains the model
Why we won
Orbit Therapeutics
3-week faster timeline. PROJ-2024-022 case study landed.
→ strengthened kb-3
Why we lost
Peak Oncology
$1.1M price gap. OEB-5 claim flagged soft by sponsor.
→ HPAPI KB entry needs SME re-verification